Evaxion A/S ADR(EVAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.05 | Insider Own | 19.22% | Shs Outstand | 8.3M | Perf Week | -22.07% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 62.5% | Insider Trans | - | Shs Float | 6.7M | Perf Month | -7.86% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.01 | Inst Own | 6.17% | Short Float | 0.99% | Perf Quarter | 5.02% |
| Income | -0.01B | P/S | 3.28 | EPS this Y | -100% | Inst Trans | 0.69% | Short Ratio | 0.29 | Perf Half Y | -34.82% |
| Sales | 0.01B | P/B | 2.56 | EPS next 5Y | - | ROA | -41.51% | Short Interest | 0.07M | Perf YTD | -38.57% |
| Book/sh | 1.14 | P/C | 1.75 | EPS past 3/5Y | 70.92% 51.86% | ROE | -110.21% | 52W High | -57.66% ($6.92) | Perf Year | -49.13% |
| Cash/sh | 1.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.95% | 52W Low | 7.72% ($2.72) | Perf 3Y | -93.73% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.33% | Gross Margin | - | Volatility(W/M) | 11.87% 9.64% | Perf 5Y | -99.23% |
| Dividend TTM | - | EV/Sales | 2.35 | Sales Y/Y TTM | 134.15% | Oper. Margin | -116.83% | ATR (14) | 0.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.06 | EPS Q/Q | 42.42% | Profit Margin | -116.42% | RSI (14) | 42.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.06 | Sales Q/Q | -100% | SMA20 | -7.83% ($3.18) | Beta | 0.61 | Target Price | $12.25 |
| Payout | - | Debt/Eq | 0.75 | Earnings | 2026/11/19 | SMA50 | -7.94% ($3.18) | Rel Volume | 0.2 | Prev Close | $3.08 |
| Employees | 46 | LT Debt/Eq | 0.69 | EPS/Sales Surpr. | - | SMA200 | -16.32% ($3.5) | Avg Volume(3M) | 0.23M | Price | $2.93 |
| IPO | 2021/2/5 | Option/Short | No/Yes | Trades | 235 | Volume | 46,205 | Change | -4.87% |
🧪 Evaxion() is a Denmark-based, Copenhagen-headquartered AI-powered techbio company that designs and develops personalized cancer vaccines and infectious disease vaccines using its "AI-Immunology" platform. Its lead candidate, EVX-01, has shown a high response rate in a Phase 2 clinical trial for advanced melanoma.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 20% of its average volume.
Next earnings report: November 19
EVAX has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -100.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $328. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.2%.
Tap to view numbers
It ranks #459 of 597 in the industry
Based on market cap of $24M.
CELU#457 Celularity Inc $26M PER - 
PLRZ#458 Polyrizon Ltd $26M PER - EVAX#459 Evaxion A/S ADR $24M PER - 
CVM#460 Cel-Sci Corp $24M PER - 
CRVO#461 CervoMed Inc $24M PER - 
FAQ
What kind of company is EVAX?
EVAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EVAX?
The market cap of EVAX is approximately $24M, ranking 5,149 within its sector.
What is the 52-week high and low for EVAX?
EVAX has recorded a 52-week high of $6.92 and a low of $2.72.
